Company profile: Immune-Onc Therapeutics
1.1 - Company Overview
Company description
- Provider of therapeutic antibodies for cancer treatment, developing IO-202, a humanized IgG1 targeting LILRB4 to deplete LILRB4-expressing cells in blood cancers, autoimmune, and inflammatory diseases; IO-108, a fully human IgG4 targeting LILRB2 to block cancer-associated immune suppression in solid tumors; and IO-312, a bispecific targeting LILRB4 and CD3 for AML and other hematologic malignancies.
Products and services
- IO-108: Fully human IgG4 monoclonal antibody targeting LILRB2, aimed at blocking cancer-associated immune suppression in solid tumors
- IO-202: Humanized IgG1 antibody targeting LILRB4, engineered to deplete LILRB4-expressing cells in blood cancers, autoimmune, and inflammatory diseases
- IO-312: Bispecific monoclonal antibody targeting LILRB4 and CD3, intended for the treatment of AML and other hematologic malignancies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Immune-Onc Therapeutics
Oncoscope
HQ: United States
Website
- Description: Provider of optical biopsy and imaging systems for epithelial tissues in the oral cavity, esophagus, stomach, colon, lung, cervix, and bladder, delivering in vivo measurements of cell nuclei diameter and density to help physicians identify pre-cancerous tissues for biopsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncoscope company profile →
Allorion Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule therapeutics for cancer and autoimmune diseases, including an EGFR L858R allosteric inhibitor program to enhance existing treatments and prevent resistance; ARTS-021, an oral CDK2 inhibitor in Phase I/II for advanced/metastatic solid tumors; ARTS-011, a selective TYK2 inhibitor in early development; and high-throughput phenotypic screening to identify Werner Helicase inhibitors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allorion Therapeutics company profile →
Avidea Technologies
HQ: United States
Website
- Description: Provider of polymer-based drugs delivering nanoparticle vaccines for cancer treatment and infectious diseases, using uniform-size nanoparticles designed to target specific tissues and cell populations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avidea Technologies company profile →
Tuhura Biosciences
HQ: United States
Website
- Description: Provider of phase 3 registration-stage immuno-oncology therapies, including personalized cancer vaccines (IFx-2.0 intratumoral pDNA expressing a bacterial protein; IFx-3.0 IV emm55 mRNA targeting CD22 for blood-related cancers) and MDSC-targeting bi-functional antibody drug conjugates (TBS-2025 Nal-anti TIGIT) to modulate immunosuppression, deliver a checkpoint inhibitor or T cell activator, and counter resistance to immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tuhura Biosciences company profile →
Biovica
HQ: Sweden
Website
- Description: Provider of blood-based biomarker assays to help oncologists monitor cancer progression, including the DiviTum® TKa Test measuring cell proliferation from solid tumors, and pharma services offering TKa testing for dose-response information, patient selection, and treatment monitoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biovica company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Immune-Onc Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Immune-Onc Therapeutics
2.2 - Growth funds investing in similar companies to Immune-Onc Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Immune-Onc Therapeutics
4.2 - Public trading comparable groups for Immune-Onc Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →